loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Bucillamine

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Bucillamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Revive Focuses On Bucillamine For Infectious Diseases
    Revive Focuses On Bucillamine For Infectious Diseases

    18 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/18/2948084/0/en/Revive-Therapeutics-Announces-Strategic-Focus-on-Bucillamine-for-Infectious-Diseases-and-Medical-Countermeasures.html

    GLOBENEWSWIRE
    18 Sep 2024
    Share Share
    Revive Therapeutics Updates On Bucillamine Research For Nerve Agents
    Revive Therapeutics Updates On Bucillamine Research For Nerve Agents

    28 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/28/2936877/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure-and-Expansion-into-Viral-Infections.html

    GLOBENEWSWIRE
    28 Aug 2024
    Share Share
    Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study
    Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study

    02 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

    GLOBENEWSWIRE
    02 Jul 2024
    Share Share
    Revive Therapeutics Updates On FDA Meeting For Long COVID Study
    Revive Therapeutics Updates On FDA Meeting For Long COVID Study

    12 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/12/2897596/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Type-C-Meeting-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

    GLOBENEWSWIRE
    12 Jun 2024
    Share Share
    Revive Requests FDA Meeting for Bucillamine Long COVID Study
    Revive Requests FDA Meeting for Bucillamine Long COVID Study

    23 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/23/2867498/0/en/Revive-Therapeutics-Announces-Type-C-Meeting-Request-Granted-by-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

    GLOBENEWSWIRE
    23 Apr 2024
    Share Share
    Revive Submits Type C Meeting Request Package to FDA for trial of Bucillamine
    Revive Submits Type C Meeting Request Package to FDA for trial of Bucillamine

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853251/0/en/Revive-Therapeutics-Submits-Type-C-Meeting-Request-Package-to-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share